Consequences of Parkinson's disease on quality of life

被引:0
作者
Parra, Nicolas [1 ]
Fernandez, Juliana [2 ]
Martinez, Oscar [3 ]
机构
[1] Inst Metropolitano Educ, Medellin, Colombia
[2] Inst Dolor Cabeza & Enfermedades Neurol, Medellin, Colombia
[3] Inst Neurol Colombia, Medellin, Colombia
来源
REVISTA CHILENA DE NEUROPSICOLOGIA | 2014年 / 9卷 / 1-2期
关键词
Parkinson's disease; neurotransmitters; quality of life; neuronal degeneration;
D O I
10.5839/rcnp.2014.090102.08
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Parkinson's disease (PD), is identified as a neurodegenerative disease, tending to attack the Central Nervous System, severely damaging neural regions of substantia nigra. Globally PD ranks second as the most prevalent neuronal degeneration disease. The origins of PD are multifactorial, because nowadays a unique biological or genetic cause to explain the etiology of full and satisfactory way is unknown. They now recognize a variety of seven types of Parkinsonism, producing affectations in its various stages, both at the serotonin, norepinephrine and acetylcholine systems. The drastic effects caused by PD on Quality of Life (QoL) of patients, can be evaluated quantitatively and scientifically and from the multiple tests and evaluations that have emerged within the field of health sciences. The four most common symptoms of Parkinsonism recognition are postural instability, body rigidity, bradykinesia and tremors. PD is still little intervened in the early stages of emergence, especially in developing nations, so that greater unity between scientific disciplines and public health systems are required to improve the QoL's populations.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 65 条
[1]  
Arias S., 2012, REV COLOMB ANTROPOL, V48, P81
[2]  
Baatile J, 2000, J REHABIL RES DEV, V37, P529
[3]  
Ball Jody, 2001, Trends in Neurosciences, V24, P367, DOI 10.1016/S0166-2236(00)01850-6
[4]   Treatment of depressive symptoms in Parkinson's disease [J].
Barone, P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 :11-15
[5]   Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems [J].
Brichta, Lars ;
Greengard, Paul ;
Flajolet, Marc .
TRENDS IN NEUROSCIENCES, 2013, 36 (09) :543-554
[6]   Parkinson disease mortality rates in Chile [J].
Chana C, Pedro ;
Jimenez C, Magdalena ;
Diaz T, Violeta ;
Juri, Carlos .
REVISTA MEDICA DE CHILE, 2013, 141 (03) :327-331
[7]   A Study of the Relationship between Health and Subjective Well-Being in Parkinson's Disease Patients [J].
Cubi-Molla, Patricia ;
de Vries, Jane ;
Devlin, Nancy .
VALUE IN HEALTH, 2014, 17 (04) :372-379
[8]  
Demey I., 2008, REV NEUROLOGICA ARGE, V33, P3
[9]   Quality of life and related concepts in Parkinson's disease: A systematic review [J].
Den Oudsten, Brenda L. ;
Van Heck, Gnus L. ;
De Vries, Jolanda .
MOVEMENT DISORDERS, 2007, 22 (11) :1528-1537
[10]   Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease? [J].
Ellis, T. ;
Cavanaugh, J. T. ;
Earhart, G. M. ;
Ford, M. P. ;
Foreman, K. B. ;
Dibble, L. E. .
PARKINSONISM & RELATED DISORDERS, 2011, 17 (09) :693-697